SLC5A2 and type 2 diabetes mellitus: Fernandes et al. performed a meta-analysis of a total of 34 randomized control trials including 63,166 patients with type 2 diabetes mellitus or heart failure for evaluating the effect of SGLT2 inhibitors on SCD (44).